ACCURACY OF AST TO PLATELET RATIO FOR PREDICTING LIVER FIBROSIS IN PATIENTS WITH CHRONIC HCV INFECTION AFTER VIRAL ERADICATION

  • C. STANCIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina Maria MUZICA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R. NASTASA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • S. ZENOVIA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. SFARTI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ermina STRATINA “Sf. Spiridon” County Clinical Emergency Hospital, Iasi
  • R. STAFIE “Sf. Spiridon” County Clinical Emergency Hospital of Iasi, Romania
  • A. ROTARU “Sf. Spiridon” County Clinical Emergency Hospital of Iasi, Romania
  • Laura HUIBAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • T. CUCIUREANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • S. CHIRIAC “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Anca TRIFAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Determining the stage of fibrosis is an essential element of chronic hepatitis C (HCV) management. This study aims to evaluate aminotransferase to platelet ratio (APRI) score in comparison with Vibration-Controlled Transient Elastography (VCTE) for assessing the severity of liver disease in HCV-infected patients. Material and methods: We retrospectively enrolled 293 HCV-infected patients with different stages of fibrosis who achieved sustained virological response (SVR) after direct-acting antivirals (DAAs) therapy, which have been evaluated by VCTE from 1st September 2020 to 30th July 2021. Results: Two hundred and ninety-three patients (72.7% females, mean age of 61.75 ± 10.87 years, and mean BMI of 27.85 ± 4.63 kg/m2) were evaluated. As estimated by VCTE, 44 (15%) of patients were without liver fibrosis (F0), 80 (27.3%) with F1 (mild), 39 (13.3%) with F2 (significant), 43 (14.7%) with F3 (advanced) liver fibrosis, and 87 (29.7%) with F4 (cirrhosis), with a mean value of liver stiffness measurements (LSM) of 10.17 ± 7.42 kPa. The APRI score has a positive correlation with the LSM score (p=0.047), predicting severe liver disease adequately. The optimal receiver operator curve (ROC) for predicting advanced fibrosis was > 1.15 (area under the curve [AUC] 0.79, 95% CI 0.71-0.83; p < 0.001) with a sensitivity (Ss) of 82.5%, specificity (Sp) 28%, a positive predictive value (PPV) of 72%, and negative predictive value (NPV) of 81%. Conclusions: APRI score can predict well the advanced liver fibrosis and cirrhosis and can be a useful non-invasive biochemical marker for resource-limited management of HCV-infected patients.

Author Biographies

C. STANCIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

Cristina Maria MUZICA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

R. NASTASA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

S. ZENOVIA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

C. SFARTI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

Ermina STRATINA, “Sf. Spiridon” County Clinical Emergency Hospital, Iasi

Institute of Gastroenterology and Hepatology

R. STAFIE, “Sf. Spiridon” County Clinical Emergency Hospital of Iasi, Romania

Institute of Gastroenterology and Hepatology

A. ROTARU, “Sf. Spiridon” County Clinical Emergency Hospital of Iasi, Romania

Institute of Gastroenterology and Hepatology

Laura HUIBAN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

T. CUCIUREANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

S. CHIRIAC, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

Anca TRIFAN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
Institute of Gastroenterology and Hepatology

References

1. ***World Health Organization. Global hepatitis report, 2017. April 2017 [cited 19 June 2021]. Avail-able from: https://www.who.int/hepatitis/publications/global-hepatitis-report 2017/ en.
2. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health 2016; 9(4): 389-395.
3. ***European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepa-titis C 2018. J Hepatol 2018; 69: 461-511.
4. Trifan A, Stanciu C, Girleanu I, et al. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: A propensity score analysis. Rev Med Chir Soc Med Nat Iasi 2021; 125(1): 54-63.
5. Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-20.
6. Lim JK, Flamm SL, Singh S, Falck-Ytter YT. Clinical Guidelines Committee of the American Gas-troenterological Association. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology 2017; 152(6): 1536-1543.
7. Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis. World J Hepatol. 2017; 9(17): 791-796.
8. Zenovia S, Stanciu C, Sfarti C, et al. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2021; 11(5): 787 / doi: 10.3390/diagnostics11050787.
9. Castéra L, Vergniol J, Foucher, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
10. ***World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Geneva: WHO Document Production Services; 2018 (cited 12 July 2021). Available from: https://www.who.int/ publications/i/item/ 9789241550345.
11. Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198.
12. Stanciu C, Muzica CM, Girleanu I, et al. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021; 22(13): 1729-1741.
13. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepato-cellular carcinoma. Intern Med 2008; 47(7): 569-575.
14. Zhang C, Wu J, Xu J, et al. Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study. Dis Markers 2019; 2019: 2046825 / doi: 10.1155/ 2019/2046825.
15. Sporea I, Sirli R, Deleanu A, et al. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol 2010; 16(38): 4832-4837.
16. Knop V, Mauss S, Goeser T, et al. German Hepatitis C-Registry. Dynamics of liver stiffness by tran-sient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. J Viral Hepat 2020; 27(7): 690-698.
17. Mendes LC, Ferreira PA, Miotto N, et al. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res 2016; 49(9): e5432 / doi: 10.1590/1414-431X20165432.
Published
2021-09-30
Section
INTERNAL MEDICINE - PEDIATRICS